0001193125-20-026871.txt : 20200206 0001193125-20-026871.hdr.sgml : 20200206 20200206170010 ACCESSION NUMBER: 0001193125-20-026871 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200206 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200206 DATE AS OF CHANGE: 20200206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYRIAD GENETICS INC CENTRAL INDEX KEY: 0000899923 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 870494517 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26642 FILM NUMBER: 20583434 BUSINESS ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: 801-584-3600 MAIL ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 8-K 1 d881361d8k.htm 8-K 8-K
MYRIAD GENETICS INC false 0000899923 0000899923 2020-02-06 2020-02-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2020

 

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

  

0-26642

  

87-0494517

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

320 Wakara Way

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Public Common Stock, $0.01 par value

  

MYGN

  

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Mark Capone as President, Chief Executive Officer and Director

(b) On February 6, 2020, Myriad Genetics, Inc. (“Myriad” or the “Company”) announced that, effective February 6, 2020, Mark C. Capone resigned as President, Chief Executive Officer and Director of the Company. Mr. Capone is expected to remain as a non-executive employee of the Company for a transition period to assist in the transition of management. Mr. Capone has served as the Company’s President and Chief Executive Officer and as a Director since 2015.

Appointment of R. Bryan Riggsbee as Interim President and Chief Executive Officer

(c) The Company also announced that R. Bryan Riggsbee, currently serving as its Executive Vice President and Chief Financial Officer, has been appointed Interim President and Chief Executive Officer of the Company effective February 6, 2020. Mr. Riggsbee will retain his current position as Chief Financial Officer of the Company. Mr. Riggsbee started with the Company in 2014.

The information required by Item 502(c)(2) with respect to Mr. Riggsbee is included in the Company’s proxy statement, filed October 16, 2019, and is incorporated herein by reference.

A copy of the press release announcing Mr. Capone’s resignation and Mr. Riggsbee’s appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.

   

Description

         
 

99.1

   

Press Release, dated February 6, 2020.

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit Index

Exhibit
No.

    

Description

         
 

99.1

   

Press release, dated February 6, 2020.

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MYRIAD GENETICS, INC.

             

Date: February 6, 2020

 

 

By:

 

/s/ R. Bryan Riggsbee

 

 

 

R. Bryan Riggsbee

 

 

 

Interim President and Chief Executive Officer, Chief Financial Officer

EX-99.1 2 d881361dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

News Release

 

Media Contact:    Ron Rogers       Investor Contact:    Scott Gleason
  

(801) 584-3065

          (801) 584-1143
   rrogers@myriad.com          sgleason@myriad.com

Myriad Announces Leadership Transition

R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO

Mark C. Capone Resigns, Effective Immediately

SALT LAKE CITY, Feb. 6, 2020 – Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that R. Bryan Riggsbee, Chief Financial Officer, has been appointed Interim President and CEO effective immediately and will also continue to serve as Chief Financial Officer. Mark C. Capone has resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors, effective immediately. Mr. Capone will remain available to the Company to assist in this transition.

“As we position Myriad for its next phase of growth and value creation, the Board and Mark have mutually agreed that now is the right time for a leadership transition,” said John T. Henderson, M.D., Chairman of the Board of Directors. “We are pleased to have a leader with Bryan’s experience to step into the additional role of Interim CEO and provide continuity as we execute on our search for a permanent CEO. Myriad has a significant opportunity to innovate around its business and position itself for sustainable, profitable growth. We are committed to taking the necessary steps to enhance our performance and are confident in the strength of our product pipeline to deliver on our value creation objectives. The Board is focused on identifying the right leader to guide the Company forward as we continue to execute on our critical success factors and position Myriad for meaningful improvement in profitability. We are confident in Bryan’s ability to drive the Company forward and will continue to support him and the entire executive team while we work to identify a permanent CEO.”

Dr. Henderson continued, “On behalf of the entire Board of Directors, I want to thank Mark for his leadership and contributions to Myriad over his more than 17-year tenure with the Company. We have had numerous scientific and medical advances during this time that have contributed significantly to the health and transformation of patients’ lives around the world. We wish him the best in his future endeavors.”

“I have been fortunate to be a part of the Myriad community for more than 17 years and I am proud of our team and what we have accomplished together, driven by our passion of supporting patients and their families around the world,” said Mr. Capone. “I am confident in the future prospects for the business and the ability of Myriad to continue its position as a world leader in personalized medicine.”

Mr. Riggsbee said, “I am committed to driving the business forward and ensuring a smooth leadership transition. We have a highly talented team of employees at Myriad and a strong foundation built upon pioneering science directed toward patient care. I intend to work closely with the Board, the rest of the executive team, and our dedicated employees as we continue to execute on our strategy to drive sustained profitable growth.”

Fiscal Second-Quarter 2020 Financial Results

In a separate release today, the Company disclosed its financial results for its fiscal second-quarter 2020 ended December 31, 2019. The Company will host a conference call with investors and analysts today at 4:30 p.m. ET to review its financial results.

About Bryan Riggsbee

Bryan Riggsbee joined Myriad in October 2014. He previously served for 10 years with Laboratory Corporation of America (LabCorp) where his most recent position was as senior vice president of Corporate Finance with responsibility for the financial planning and analysis and treasury functions. Prior to LabCorp, Mr. Riggsbee served in various finance roles with General Electric and began his career in the audit division of KPMG. He received a B.A. in Accounting from North Carolina State University, a B.A. in political science from the University of North Carolina at Chapel Hill and an M.B.A. from Northwestern University. Mr. Riggsbee is a Certified Public Accountant licensed in the State of North Carolina.

About Myriad Genetics

Myriad Genetics Inc. is a leading molecular diagnostic and precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

 

2

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes,” “potential,” “could,” “would,” “continue,” “likely,” “will,” “strategy, “goal” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of the Company’s existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to the Company’s ability to transition from its existing product portfolio to its new tests; risks related to changes in the governmental or private insurers’ coverage and reimbursement levels for the Company’s tests or its ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests and services; the risk that the Company may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that the Company may not successfully develop new markets for its molecular diagnostic tests and pharmaceutical and clinical services, including its ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying the Company’s molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating the Company’s laboratory testing facilities; risks related to public concern over the Company’s genetic testing in general or the Company’s tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to the Company’s ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to the Company’s ability to successfully integrate and derive benefits from any technologies or businesses that it licenses or acquires, including but not limited to its acquisition of Counsyl, Assurex, Crescendo, Sividon and the Clinic; risks related to the Company’s projections about the potential market opportunity for its products; the risk that the Company or its licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying the Company’s tests; the risk of patent-infringement claims or challenges to the validity of the Company’s patents; risks related to changes in intellectual property laws covering the Company’s molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against the Company by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that the Company may be unable to comply with financial operating covenants under its credit or lending agreements: the risk that the Company will be unable to pay, when due, amounts due under its creditor lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of the Company’s Annual report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in the Company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

 

3

EX-101.SCH 3 mygn-20200206.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mygn-20200206_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 mygn-20200206_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g881361g0206215502839.jpg GRAPHIC begin 644 g881361g0206215502839.jpg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end EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d881361d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d881361d8k.htm" ] }, "labelLink": { "local": [ "mygn-20200206_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mygn-20200206_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mygn-20200206.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mygn", "nsuri": "http://www.myriad.com/20200206", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d881361d8k.htm", "contextRef": "duration_2020-02-06_to_2020-02-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d881361d8k.htm", "contextRef": "duration_2020-02-06_to_2020-02-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.myriad.com//20200206/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d881361d8k.htm d881361dex991.htm mygn-20200206.xsd mygn-20200206_lab.xml mygn-20200206_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 13 0001193125-20-026871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-026871-xbrl.zip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end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information
Feb. 06, 2020
Cover [Abstract]  
Entity Registrant Name MYRIAD GENETICS INC
Amendment Flag false
Entity Central Index Key 0000899923
Document Type 8-K
Document Period End Date Feb. 06, 2020
Entity Incorporation State Country Code DE
Entity File Number 0-26642
Entity Tax Identification Number 87-0494517
Entity Address, Address Line One 320 Wakara Way
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84108
City Area Code (801)
Local Phone Number 584-3600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Public Common Stock, $0.01 par value
Trading Symbol MYGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

XML 16 d881361d8k_htm.xml IDEA: XBRL DOCUMENT 0000899923 2020-02-06 2020-02-06 MYRIAD GENETICS INC false 0000899923 8-K 2020-02-06 DE 0-26642 87-0494517 320 Wakara Way Salt Lake City UT 84108 (801) 584-3600 false false false false Public Common Stock, $0.01 par value MYGN NASDAQ false